Polyrizon Ltd. (PLRZ )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PLRZ
- Company Polyrizon Ltd.
- Price $1.57
- Changes Percentage -32.62
- Change -0.76
- Day Low $1.26
- Day High $2.19
- Year High $4.8
- Year Low $0.77
- Market Cap $6,347,877
- Price Avg 50 EMA (D) $1.16
- Price Avg 200 EMA (D) $1.16
- Exchange NASDAQ
- Volume 1,356,394
- Average Volume 4,334,372
- Open $2
- Previous Close $2.33
- EPS -0.24
- PE -6.54
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $4,043,234
Company brief: POLYRIZON LTD. (PLRZ )
- Healthcare
- Biotechnology
- Mr. Tomer Izraeli
- https://www.polyrizon-biotech.com
- IL
- N/A
- 10-29-2024
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
PLRZ Corporation News
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
globenewswire.com -- Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intra...
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
globenewswire.com -- The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilitie...